Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

21.04.15	Biogen Records Consistent Long Term Safety/Efficacy Data For Plegridy (RTTNews)
21.04.15	PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients (Businesswire)
21.04.15	International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction (Businesswire)
20.04.15	Biogen : Tecfidera Data Reinforce Efficacy For Newly-Diagnosed MS Patients (RTTNews)
20.04.15	TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients (Businesswire)
14.04.15	Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair (Businesswire)
07.04.15	Biogen Data at AAN Annual Meeting Underscore Commitment to Advancing Patient Care in Neurology (Businesswire)
30.03.15	Biogen Reports EMA Validation Of Marketing Authorization Application For SB2 (RTTNews)
30.03.15	Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab (Businesswire)
27.03.15	Biogen: EMA Validates MAA For ZINBRYTA - Quick Facts (RTTNews)
27.03.15	European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS (Businesswire)
23.03.15	Biogen Idec Becomes Biogen - Quick Facts (RTTNews)
20.03.15	Biogen Alzheimer's Drug May Be Elusive Breakthrough, Study Shows (RTTNews)
20.03.15	Biogen: Aducanumab Shows Significant Reduction On Amyloid Plaque Levels (RTTNews)
06.03.15	Isis Earns $9 Mln Milestone Payment From Biogen Idec (RTTNews)
27.02.15	Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX® Pediatric Study (Businesswire)
19.02.15	Biogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways (Businesswire)
30.01.15	Biogen Idec Shares Surge 7% As Q4 Adj Profit Tops View, Rosy Outlook (RTTNews)
29.01.15	Biogen Profit Crushes Estimates, FY15 EPS Guidance Strong; Stock Up 7% (RTTNews)
29.01.15	Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion (Businesswire)
29.01.15	Biogen Idec Teams Up To Develop Gene Therapies For Hemophilia (RTTNews)
29.01.15	Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia (Businesswire)
12.01.15	Biogen Idec To Acquire Convergence Pharma - Quick Facts (RTTNews)
12.01.15	Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals (Businesswire)
09.01.15	Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research (Businesswire)
08.01.15	Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial (RTTNews)
08.01.15	Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis (Businesswire)
26.11.14	Why Tecfidera Drug Label Is Updated... (RTTNews)
31.10.14	Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review (Businesswire)
22.10.14	Biogen Idec Earnings Surge Above Estimates, Lifts 2014 Outlook (RTTNews)
22.10.14	Biogen Idec Q3 Results Top Estimates; Lifts Full-year EPS View - Quick Facts (RTTNews)
22.10.14	Earnings Watch For October 22 (BA, BSX, XRX, CA, ABT, T) (RTTNews)
12.09.14	Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) (Businesswire)
11.09.14	Biogen Idec's Phase 3 Study With Tecfidera Show Positive Data Over 5 Years (RTTNews)
11.09.14	Biogen Idec: PLEGRIDY Maintains Positive Treatment Effects In Phase 3 Trial (RTTNews)
11.09.14	PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients (Businesswire)
11.09.14	New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients (Businesswire)
03.09.14	Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care (Businesswire)
26.08.14	Biogen Idec: Health Canada Approves ELOCTATE - Quick Facts (RTTNews)
26.08.14	Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub (Businesswire)
21.08.14	Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions (Businesswire)
16.08.14	Biogen Idec: FDA Approves Plegridy To Treat Multiple Sclerosis (RTTNews)
23.07.14	PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis (Businesswire)
23.07.14	PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis (Businesswire)
16.06.14	Biogen Idec, AbbVie Announce Positive Results From Phase 3 DECIDE Clinical Trial (RTTNews)
07.06.14	Biogen Idec: FDA Okays Eloctate To Treat Hemophilia A (RTTNews)
30.05.14	Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses (Businesswire)
28.05.14	Array BioPharma Inks Drug Discovery Collaboration Deal With Biogen Idec (RTTNews)
28.05.14	Biogen Idec Announces Official Partnership with Sailing Sclerosis’ "Oceans of Hope” to Globally Change Perceptions of MS (Businesswire)
23.05.14	Biogen Idec Receives Positive CHMP Opinion For Plegridy As Treatment For MS (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

26.11.24		Dow Jones aktuell: Dow Jones zum Handelsende in Grün
26.11.24		Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100
26.11.24		Börse New York: Dow Jones wenig verändert
26.11.24		Starker Wochentag in New York: NASDAQ 100-Anleger greifen am Nachmittag zu
26.11.24		Starker Wochentag in New York: S&P 500 präsentiert sich fester
26.11.24		Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester
26.11.24		Optimismus in New York: S&P 500 legt am Dienstagmittag zu
26.11.24		Pluszeichen in New York: NASDAQ Composite mittags in Grün

26.11.24

Dow Jones aktuell: Dow Jones zum Handelsende in Grün

26.11.24

Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100

26.11.24

Börse New York: Dow Jones wenig verändert

26.11.24

Starker Wochentag in New York: NASDAQ 100-Anleger greifen am Nachmittag zu

26.11.24

Starker Wochentag in New York: S&P 500 präsentiert sich fester

26.11.24

Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester